Titan Pharmaceuticals logo

Titan PharmaceuticalsNASDAQ: TTNP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

18 January 1996

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$3.69 M
-84%vs. 3y high
10%vs. sector
-vs. 3y high
-vs. sector
-92%vs. 3y high
39%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 19 min ago
$4.03-$0.27(-6.17%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

TTNP Latest News

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. – TTNP
globenewswire.com05 September 2024 Sentiment: NEUTRAL

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Titan Pharmaceuticals , Inc. ( Nasdaq : TTNP ), relating to its proposed merger with BSKE Ltd. Under the terms of the agreement, Titan shareholders are expected to own approximately 13.3% of the combined company.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. - TTNP
prnewswire.com04 September 2024 Sentiment: NEUTRAL

NEW YORK , Sept. 4, 2024 /PRNewswire/ --  Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.

Shareholder Alert: Ademi LLP investigates whether Titan Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders
prnewswire.com23 August 2024 Sentiment: NEGATIVE

MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Titan (NASDAQ: TTNP) for possible breaches of fiduciary duty and other violations of law in its transaction with KE Sdn. Bhd. Click here to learn how to join our investigation https://www.ademilaw.com/case/titan-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

TTNP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Titan Pharmaceuticals, Inc. Is Fair to Shareholders
businesswire.com19 August 2024 Sentiment: NEUTRAL

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) and KE Sdn. Bhd. is fair to Titan shareholders. Upon closing of the proposed transaction, Titan shareholders expect to own approximately 13.3% of the combined company. Halper Sadeh encourages Titan shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sade.

Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.
globenewswire.com19 August 2024 Sentiment: POSITIVE

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”). The Merger Agreement was approved by Titan's board of directors (the “Board”). If the Merger Agreement is approved by the stockholders of Titan and KE (and the other closing conditions are satisfied or waived in accordance with the Merger Agreement), and upon consummation of the transactions contemplated by the Merger Agreement (the “Closing”), Titan will be combined with KE in a “reverse merger” transaction consisting of two steps:

What type of business is Titan Pharmaceuticals?

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

What sector is Titan Pharmaceuticals in?

Titan Pharmaceuticals is in the Healthcare sector

What industry is Titan Pharmaceuticals in?

Titan Pharmaceuticals is in the Biotechnology industry

What country is Titan Pharmaceuticals from?

Titan Pharmaceuticals is headquartered in United States

When did Titan Pharmaceuticals go public?

Titan Pharmaceuticals initial public offering (IPO) was on 18 January 1996

What is Titan Pharmaceuticals website?

https://www.titanpharm.com

Is Titan Pharmaceuticals in the S&P 500?

No, Titan Pharmaceuticals is not included in the S&P 500 index

Is Titan Pharmaceuticals in the NASDAQ 100?

No, Titan Pharmaceuticals is not included in the NASDAQ 100 index

Is Titan Pharmaceuticals in the Dow Jones?

No, Titan Pharmaceuticals is not included in the Dow Jones index

When was Titan Pharmaceuticals the previous earnings report?

No data

When does Titan Pharmaceuticals earnings report?

The next expected earnings date for Titan Pharmaceuticals is 14 November 2024